Table 1.

Effect of endostar on the radioresponse of human nasopharyngeal carcinoma (HNE) and human lung adenocarcinoma (SPC‐A1) tumor xenografts

Tumor type	HNE tumor xenografts				SCP‐A1 tumor xenografts
	Time required for tumor to grow four times volume (days) (mean ± SD)	Absolute growth delay (days) †	Normalized growth delay (days) ‡	Enhancement factor §	Time required for tumor to grow four times volume (days) (mean ± SD)	Absolute growth delay (days)	Normalized growth delay (days)	Enhancement factor
Sham	10 ± 1.7				9 ± 1.6
Endostar	17 ± 3.1	7			15 ± 2.3	6
Radiation therapy	27 ± 7.5	17			29 ± 5.5	20
Endostar plus radiation therapy	44 ± 4.5	34	>27	1.6	47 ± 7.6	38	>32	1.61

^† Absolute tumor growth delay caused by radiation, endostar, or both agents is defined as the time in days that tumors required to reach four times the volume of the time of treatment initiation minus the time in days required by control tumors to grow to four times the volume.

^‡ Normalized tumor growth delay is defined as the time in days for tumors to reach four times the volume in mice treated with the combination of endostar and radiation therapy minus the time in days to reach four times the volume in mice treated with endostar only.

^§ Enhancement factors were obtained by dividing normalized tumor growth delay in mice treated with endostar plus radiation therapy with the absolute growth delay in mice treated with radiation only.